Bio-Rad Laboratories, Inc. (bio)
BIO — Company Overview
Bio-Rad Laboratories, Inc. (BIO) is a large-cap company in the Healthcare sector, operating in Medical Devices.
| Ticker | BIO |
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | NYQ |
| Market cap | $10.13B |
| Last price | $378.88 |
| Size category | Large Cap |
BIO — Business Description
Bio-Rad Laboratories, Inc. (BIO) operates in Medical Devices within the broader Healthcare market. Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities a…
Official website: https://www.bio-rad.com.
BIO — Investment Thesis
The investment thesis for Bio-Rad Laboratories, Inc. (BIO) rests on how Healthcare dynamics, profitability, and valuation interact at today's price.
- Revenue is contracting at roughly -0.1% year-over-year (public data).
- Trailing P/E of 46.20× implies elevated growth expectations at the current price.
- Forward P/E (37.78×) is below trailing P/E — earnings may be expected to improve.
- Equity market capitalization is approximately $10.13B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
BIO — Financial Health
Financial health for Bio-Rad Laboratories, Inc. (BIO) is summarized from publicly reported profitability, leverage, and cash-flow metrics.
Profit margin near 8.6% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $283.19M supports balance-sheet flexibility.
| Trailing P/E | 46.20× |
| Forward P/E | 37.78× |
| Price / Sales | 3.92× |
| Price / Book | 1.41× |
| Gross margin | 52.0% |
| Operating margin | 11.2% |
| Profit margin | 8.6% |
| Return on equity | 3.1% |
| Debt / Equity | 19.10 |
| Free cash flow | $283.19M |
BIO — Growth Outlook
Growth outlook for Bio-Rad Laboratories, Inc. (BIO) depends on demand trends in Medical Devices and the company's ability to convert revenue into sustainable earnings.
- Revenue decline of -0.1% highlights near-term demand headwinds.
- Earnings growth of 18.7% year-over-year supports improving profitability.
- Price is 4.4% below the 52-week high.
BIO — Competitive Position
Bio-Rad Laboratories, Inc. (BIO) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Medical Devices.
- Market capitalization of $10.13B places BIO among large-cap peers.
- Gross margin near 52.0% may reflect pricing power or favorable mix.
BIO — Strengths
Strengths for Bio-Rad Laboratories, Inc. (BIO) inferred from public financial metrics:
- Earnings growth of 18.7% year-over-year.
- Gross margin of 52.0% supports competitive unit economics.
- Positive free cash flow ($283.19M).
- Moderate leverage (debt/equity 19.10).
- Large Cap scale ($10.13B) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
BIO — Weaknesses
Weaknesses and pressure points for Bio-Rad Laboratories, Inc. (BIO) based on available data:
- Revenue contraction of -0.1% year-over-year.
- Elevated trailing P/E (46.20×) limits valuation margin of safety.
BIO — Opportunities
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
BIO — Risks
- Rich valuation (P/E 46.20×) increases downside if growth slows.
- Negative revenue growth may signal share loss or cyclical pressure.
BIO — Summary
Bio-Rad Laboratories, Inc. (BIO) is a large-cap Healthcare company focused on Medical Devices, listed on NYQ. Last price $378.88 with market cap $10.13B. Trailing P/E 46.20×. Revenue declined -0.1% year-over-year per public data. Notable strengths include earnings growth of 18.7% year-over-year. Key watch items include revenue contraction of -0.1% year-over-year. Public estimates and earnings snapshots for Bio-Rad Laboratories, Inc. are on this site; ownership, live news, and deeper models remain in Vest Terminal.
Start Free — open BIO in Vest Terminal
Access live data, filings, ownership, and analysis for Bio-Rad Laboratories, Inc..
Bio-Rad Laboratories, Inc. FAQ
What does Bio-Rad Laboratories, Inc. (BIO) do?
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The…
What is BIO's P/E ratio?
Bio-Rad Laboratories, Inc. has a trailing P/E of 46.20× based on publicly available market data.
Does BIO pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is BIO in?
Bio-Rad Laboratories, Inc. is classified in Healthcare (Medical Devices) on NYQ.
What is BIO's market capitalization?
Approximate market cap: $10.13B.
What are the main risks for BIO?
Key risks include elevated valuation, negative revenue growth, among factors on this page.
What are the strengths of BIO?
Potential positives include earnings growth of 18.7% year-over-year, gross margin of 52.0% supports competitive unit economics.
Where can I get analyst estimates for BIO?
Public analyst price targets and consensus for Bio-Rad Laboratories, Inc. are on the free /stocks/bio/estimates page. Deeper estimate history and models are available in Vest Terminal.